Publications by authors named "Enriqueta Felip"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

428

Total Likes

222

Extended Reach

813,725

Social Features

112
F
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng

J Immunother Cancer· February 2024

Videos about Article: user

1 15 2 3

View All Article and Social Media Activity
H
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis Paz-Ares, Benjamin Besse

J Clin Oncol· December 2023

Videos about Article: user

1 2 95 1 18

View All Article and Social Media Activity
A
Amivantamab Plus Lazertinib in Atypical -Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Pascale Tomasini, Yongsheng Wang, Yongsheng Li, Enriqueta Felip, Lin Wu

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, Suresh S Ramalingam, Myung-Ju Ahn

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer.
Erwin De Cock, Sabine Oskar, Cecilia Lourdudoss, Renata Eiras, M Catherine Pietanza, Enriqueta Felip

Adv Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
Enriqueta Felip, Heather A Wakelee, Chenqi Fu, Yu Deng, Fanny Masson

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.
Elena Garralda, Charles Abbott, Alma Calahorro, Oriol Mirallas, Jason Pugh, Enriqueta Felip

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Enriqueta Felip

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, Susanna Cheng, Enriqueta Felip

Target Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Pasi A Jänne, David Planchard, Koichi Goto, Egbert F Smit, Adrianus Johannes de Langen, Enriqueta Felip

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.
Pablo Jimenez-Labaig, Oriol Mirallas, Ana Isabel Martin-Quesada, Antonio Rullan, Dario Trapani, Enriqueta Felip

J Immunother Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, Yun Fan, Dongqing Lv, Enriqueta Felip

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
Byoung Chul Cho, Weimin Li, Alexander I Spira, Maxwell Sauder, Jill Feldman, Enriqueta Felip

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].
Marina C Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip

JTO Clin Res Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
Martin Reck, Jyoti D Patel, Jhanelle E Gray, Noemí Reguart, Manuel Cobo, Enriqueta Felip

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.
Divyan Chopra, Zhiyi Lan, David M Waterhouse, Jürgen Wolf, Enriqueta Felip

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, Makoto Nishio, Melissa L Johnson, Enriqueta Felip

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F Sanmamed

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
Anne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, Astrid Paulus, Sang-We Kim, Enriqueta Felip

Lung Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis.
Jay M Lee, Alessandro Brunelli, Amy L Cummings, Enriqueta Felip, Catherine A Shu

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.
David R Jones, Isabelle Opitz, David Harpole, Jane Yanagawa, Eric Lim, Enriqueta Felip

J Thorac Cardiovasc Surg· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
Nancee Pronsati, Geoffrey Liu, Todd M Bauer, Enriqueta Felip, Yasushi Goto

Lung Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.
Francois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, Alona Zer, Laurent Greillier

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adagrasib versus docetaxel in KRAS-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
Fabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, Ludovic Doucet, Aitor Azkárate Martínez, Enriqueta Felip

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights on Oligometastatic Non-Small-Cell Lung Cancer.
Augusto Valdivia, Pau Mascaro-Baselga, Clara Salva-de Torres, Abraham Geng-Cahuayme, Sara Torresan, Enriqueta Felip

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis